Targeting CHK1 significantly increased the sensitivity to radiotherapy and the accumulation of cytosolic ssDNA, promoting cGAS/STING-mediated type I IFN production via TBK1/IRF3 and increasing cancer immunogenicity to recruit dendritic cells and enhance their maturation for the T-cell response in ARID1A-deficient tumors (Fig. 6K). Here, ARID1A is linked to cancer.